

### PURPOSE

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

### PRODUCT

|  |  |
|--|--|
| <b>PRODUCT NAME</b>                                  | <b>PUT WARRANTS ON BASILEA PHARMACEUTICA LTD</b>   |
| <b>PRODUCT IDENTIFIERS</b>                           | ISIN: CH1566051749; Valor: 156605174 ; Symbol: BSDPJB  |
| <b>PRIIP MANUFACTURER</b>                            | Bank Julius Baer & Co. Ltd., Zurich ("Julius Baer") ( <a href="https://derivatives.juliusbaer.com/en/home">https://derivatives.juliusbaer.com/en/home</a> )<br>Call +41 (0)58 888 8181 for more information. The PRIIP Manufacturer is part of the Julius Baer Group.  |
| <b>COMPETENT AUTHORITY OF THE PRIIP MANUFACTURER</b> | Swiss Financial Market Supervisory Authority (FINMA) – FINMA is not considered a competent supervisory authority under EU Regulation 1286/2014 on Key Information Documents for Packaged Retail and Insurance-based Investment Products (PRIIPs) in the technical sense, as Switzerland is not a member of the EU. |
| <b>DATE AND TIME OF PRODUCTION OF THE KID</b>        | 25 June 2026 01:13:43 CET  |

**YOU ARE ABOUT TO PURCHASE A PRODUCT THAT IS NOT SIMPLE AND MAY BE DIFFICULT TO UNDERSTAND.**

## 1. WHAT IS THIS PRODUCT?

**TYPE:** Swiss law governed notes.

**TERM:** The term of the product ends on the Final Redemption Date, unless the product has been terminated or redeemed early.

**OBJECTIVES:** Put Warrants are leveraged products and allow you to benefit, with leverage, from a decrease in the value of the underlying. Due to the leveraged nature of the products, a small amount invested can generate higher returns but also higher losses than will be reflected in the gains and losses respectively in the value of the underlying.

The number of products specified in the Ratio grant you the right to sell upon exercise the specified underlying to the manufacturer for an amount in cash equal to the Exercise Price/Strike with delivery on the Settlement Date. Therefore, if the value of the underlying is below the Exercise Price/Strike upon exercise, you will benefit, with leverage, from a decrease in the value of the underlying because you will be able to sell the underlying at the higher Exercise Price/Strike. Thus, the potential return on the product corresponds to the difference between the value of the underlying upon the Settlement Date and the Exercise Price/Strike. However, the maximum potential profit is limited and reached once the value of the underlying is equal to zero. Alternatively, if the products have not previously been exercised and the value of the underlying is **at or above** the Exercise Price/Strike upon expiration, you will suffer a total loss of your investment.

**EXERCISE RIGHT:** Unless previously redeemed, repurchased or cancelled, the number of products specified in the Ratio entitles you upon exercise during the Exercise Period to sell on the Settlement Date the number of Shares specified in the Ratio to the manufacturer for an amount in cash equal to the Exercise Price/Strike per Share. Products not exercised by the Expiration Time on the Expiration Date shall expire worthless and become null and void at such time.

**EXERCISE CONDITIONS:** The products may only be exercised in such number representing the Exercise Lot or multiples thereof, on any Exchange Business Day during the Exercise Period. An Exercise Notice shall be delivered by you, together with the relevant Products, to the Specified Office. Any determination by the manufacturer as to whether an Exercise Notice is complete or in proper form or is delivered in a timely manner shall, absent manifest error, be conclusive and binding.

**SETTLEMENT TYPE:** Physical settlement means, the payment of the Exercise Price/Strike per Share by the manufacturer to you against delivery of the number of Shares specified in the Ratio by you to the manufacturer. You shall also pay all taxes, stamp duties, other fees or commissions due at the time of the exercise of the products.

**SECONDARY MARKET:** Products may have no established trading market when issued and one may never develop. If a market does develop, it may not be liquid. Therefore, you may not be able to sell your Products easily or at prices reasonably acceptable to you. Under normal market circumstances, the manufacturer will endeavour to provide a secondary market for products, but is under no obligation to do so. Upon your demand, the manufacturer will endeavour to provide bid/offer prices for products, depending on actual market conditions. There will be a price difference between bid and offer prices (spread).

The product terms also provide that if certain extraordinary events occur, adjustments may be made to the product and Julius Baer may terminate the product early. These events are specified in the product terms and principally relate to the underlyings, the product and the product manufacturer. Therefore, investors should be prepared to sustain a partial or total loss of their investments.

|                           |   |                                     |   |
|---------------------------|---|-------------------------------------|---|
| <b>Issue Currency</b>     | CHF   | <b>Expiration Date</b>              | 18 December 2026 - If not an Exchange Business Day, the immediately following Exchange Business Day shall be deemed to be the Expiration Date.  |
| <b>Exercise Currency</b>  | CHF   | <b>Expiration Time</b>              | Scheduled Closing Time  |
| <b>Issue Price</b>        | CHF 0.38  | <b>Settlement Type</b>              | Physical settlement or cash settlement  |
| <b>Exercise Style</b>     | American  | <b>Settlement Date</b>              | 3 Business Days after the Exercise Date excluding the Exercise Date, being the date on which any cash payment or delivery of underlying(s) due under the relevant products upon exercise shall be made. |
| <b>Initial Volatility</b> | 38.26%  | <b>Last Trading Date</b>            | 18 December 2026, until 12:00 CET   |
| <b>Initial Delta</b>      | -46.72%   | <b>Specified Office</b>             | Bank Julius Baer & Co. Ltd., Zurich, Switzerland  |
| <b>Initial Gearing</b>    | 8.64x   | <b>Paying Agent/ Exercise Agent</b> | Bank Julius Baer & Co. Ltd., Zurich and any agents or other persons acting on behalf of such Paying Agent and any successor appointed by the manufacturer.  |
| <b>Initial Premium</b>    | 10.11%  |                                     |   |
| <b>Ratio</b>              | with respect to the underlying, the Denomination divided by its Strike Price  |                                     |   |
| <b>Launch Date</b>        | 17 June 2026  |                                     |   |
| <b>Issue Date</b>         | 18 June 2026  |                                     |   |
| <b>Exercise Period</b>    | from 17 June 2026 to 18 December 2026   |                                     |   |
| <b>Exercise Date</b>      | with respect to any product, the Exchange Business Day during the Exercise Period on which such product is exercised. |                                     |   |
| <b>Exercise Lot</b>       | 15 products and multiples thereof, being the smallest number of products required in order to exercise the products.  |                                     |   |

### UNDERLYING

| Name                      | ISIN         | Initial Level | Exercise Price/Strike | Ratio  | Exchange           |
|---------------------------|--------------|---------------|-----------------------|--------|--------------------|
| Basilea Pharmaceutica Ltd | CH0011432447 | CHF 49.25     | CHF 50.00             | 0.0667 | SIX Swiss Exchange |

### INTENDED RETAIL INVESTOR

The product is intended to be offered to retail investors who fulfil all of the criteria below:

- Have sufficient knowledge and experience and a comprehensive understanding of the product, its market and its specific risks, either independently or through professional advice;
- Have the ability to bear a total loss of their investment;
- Have an investment horizon of the recommended holding period specified below;
- Seek income, expect the movement in the underlying to perform in a way that generates a favourable return;

- Are willing to accept a level of risk to achieve potential returns that is consistent with the summary risk indicator shown below.

## 2. WHAT ARE THE RISKS AND WHAT COULD I GET IN RETURN?

### RISK INDICATOR



The risk indicator assumes you keep the product until 18 December 2026. The actual risk can vary significantly if you cash in at an early stage and you may get back less. You may not be able to sell your product easily or may have to sell at a price that significantly impacts on how much you get back.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because Julius Baer is not able to pay you.

Julius Baer has classified this product as 7 out of 7, which is the highest risk class. This rates the potential losses from future performance at a very high level, and poor market conditions are very unlikely to impact Julius Baer's capacity to pay you.

**Be aware of currency risk. If the currency of your account is different to that of this product, you will be exposed to currency risk, so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.**

In case of physical delivery of the underlying on termination of the product, you may incur a loss if the value of the underlying decreases between termination of the product and the date when it is credited to your securities account.

This product does not include any protection from future market performance, so you could lose some or all of your investment.

If Julius Baer is not able to pay you what is owed, you could lose your entire investment.

### PERFORMANCE SCENARIOS

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted. The scenarios shown are illustrations based on results from the past and on certain assumptions. Markets could develop very differently in the future.

**Recommended holding period: 18 December 2026**

**Example Investment: CHF 10,000**

**If you exit after 18 December 2026**

| <b>Minimum</b>      | There is no minimum guaranteed return. You can lose some or all of your investment. |                                 |
|---------------------|---|---------------------------------|
| <b>Stress</b>       | <b>What you might get back after costs</b><br>Percentage return (not annualised)    | <b>CHF 0.00</b><br>-100.00%     |
| <b>Unfavourable</b> | <b>What you might get back after costs</b><br>Percentage return (not annualised)    | <b>CHF 0.00</b><br>-100.00%     |
| <b>Moderate</b>     | <b>What you might get back after costs</b><br>Percentage return (not annualised)    | <b>CHF 0.00</b><br>-100.00%     |
| <b>Favourable</b>   | <b>What you might get back after costs</b><br>Percentage return (not annualised)    | <b>CHF 25,610.00</b><br>156.10% |

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

The stress scenario shows what you might get back in extreme market circumstances.

The above scenarios are possible outcomes which have been calculated on the basis of simulations. In case of an early redemption the simulation assumes that no reinvestment is made.

This product cannot be easily cashed in. If you exit the investment earlier than the recommended holding period you do not have a guarantee and you may have to pay extra costs.

## 3. WHAT HAPPENS IF JULIUS BAER IS UNABLE TO PAY OUT?

You are exposed to the risk that Julius Baer might be unable to meet its obligations in connection with the product for instance in the event of bankruptcy or an official directive for resolution action. This may materially adversely affect the value of the product and could lead to you losing some or all of your investment in the product. The product is not a deposit and as such is not covered by any deposit protection scheme.

## 4. WHAT ARE THE COSTS?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

### COSTS OVER TIME

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest and how long you hold the product. The amounts shown here are illustrations based on an example investment amount and different investment periods.

We have assumed:

- You would get back the amount that you invested (0 % annual return).
- CHF 10,000 is invested

|                 | <b>If you exit after 18 December 2026</b> |
|-----------------|---|
| Total costs     | CHF 0                                     |
| Cost impact (*) | 0.0%                                      |

(\*) This illustrates how costs reduce your return over the holding period. For example it shows that if you exit at the recommended holding period your return is projected to be -100.00% before costs and -100.00% after costs.

We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

### COMPOSITION OF COSTS

|   |  | <b>If you exit after 18 December 2026</b> |
|---|--|---|
| <b>One-off costs upon entry or exit</b>                     |  |   |
| Entry costs   | The impact of the costs already included in the price              | CHF 0                                     |
| Exit costs  | The impact of the costs of exiting your investment when it matures | CHF 0                                     |
| <b>Ongoing costs</b>  |  |   |
| Management fees and other administrative or operating costs | There is no management fee for this product                        | -   |

---

Transaction costs -

---

## 5. HOW LONG SHOULD I HOLD IT AND CAN I TAKE MONEY OUT EARLY?

---

### **Recommended holding period: 18 December 2026 (maturity date)**

The product aims to provide you with the return described under “1. What is this product?” above. However, this only applies if the product is held to maturity.

Disinvestment can only be done by selling the product either through the exchange (if the product is listed) or off-exchange, where an offer for such product exists. No fees or penalties will be charged by Julius Baer for any such transaction, however an execution fee might be chargeable by your broker if applicable. By selling the product before its maturity, you may receive back less than you would have received if you had kept the product until maturity.

In volatile or unusual market conditions, or in the event of technical disruptions, the sale of the product can be temporarily hindered or suspended and may not be possible at all.

## 6. HOW CAN I COMPLAIN?

---

Complaints about the conduct of the person advising on, or selling the product, may be submitted directly to that person or their supervisors. Complaints about the product or the conduct of the manufacturer of this product may be raised in writing to the following address: Bank Julius Baer & Co. Ltd., Hohlstrasse 604/606, P.O. Box, 8010 Zurich, Switzerland and by email to: [derivatives@juliusbaer.com](mailto:derivatives@juliusbaer.com) or via the following website: <https://derivatives.juliusbaer.com/en/home>.

## 7. OTHER RELEVANT INFORMATION

---

The information contained in this Key Information Document does not constitute a recommendation to enter into the product and is no substitute for individual consultation with your bank or advisor.

Any additional documentation in relation to the product, in particular, the issuance programme documentation, any supplements thereto and the product terms are available free of charge from Bank Julius Baer & Co. Ltd., Hohlstrasse 604/606, P.O. Box, 8010 Zurich, Switzerland (<https://derivatives.juliusbaer.com/en/home>).

The performance scenarios presented in this Key Information Document (KID) are based on a methodology, as set out in the EU Regulation 1286/2014 on Key Information Documents for Packaged Retail and Insurance-based Investment Products (PRIIPs) and its supplementing regulations. Compliance with the prescribed calculation methodology may result in unrealistic performance scenarios and values for a number of products.